Study of OBI-902 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called OBI-902 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if OBI-902 can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor that has spread or cannot be removed by surgery and has not responded to standard treatments (or you have chosen not to receive standard treatments).
- You have at least one measurable tumor (visible on scans).
- You are able to perform daily activities with minimal help (ECOG score 0 or 1).
- Your liver, kidney, and blood test results are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
This phase 1 study tests an experimental drug called ONC 841 for people with advanced solid tumors that have not responded to other treatments. The trial aims to find a safe dose and see if the drug can shrink tumors.
This Phase 1/2 trial tests IMP9064, either alone or with another treatment, in people with advanced solid cancers that have stopped responding to standard care. It aims to see how well it works and how safe it is, including whether it can be used when treatment options are limited.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.